Related Experiment Video
Updated: Jul 5, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Onset of cardiac iron loading in pediatric patients with thalassemia major
John C Wood1, Raffaella Origa, Annalisa Agus
1Division of Cardiology, Mailstop 34, Children's Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. jwood@chla.usc.edu
Insights
Cardiac iron screening in thalassemia major patients is best timed by age and transfusion history, not just iron levels. Younger children (under 9.5 years) rarely show cardiac iron, suggesting later screening is often appropriate.
Area of Science:
- Pediatric Cardiology
- Medical Imaging
- Hematology
Background:
- Thalassemia major patients require frequent blood transfusions, leading to iron overload.
- Cardiac iron loading is a major cause of morbidity and mortality in these patients.
- Early detection of cardiac iron is crucial for timely intervention.
Purpose of the Study:
- To determine the optimal timing for cardiac iron screening using magnetic resonance imaging (MRI) in pediatric patients with thalassemia major.
- To evaluate the relationship between patient age, transfusional iron burden, and cardiac iron levels.
- To assess the predictive value of liver iron and ferritin levels for cardiac iron loading.
Main Methods:
- Retrospective review of cardiac T2* assessments in 77 thalassemia major patients aged 2.5 to 18 years.
- Analysis of cardiac iron detection rates based on age groups.
- Correlation of cardiac iron with transfusional iron history, liver iron, and ferritin levels.
Main Results:
- No cardiac iron was detected in patients younger than 9.5 years.
- Cardiac iron was present in 36% of patients aged 15-18 years (odds ratio of 1.28 per year).
- All patients with cardiac iron had received at least 35 grams of transfusional iron; liver iron and ferritin did not predict cardiac iron.
Conclusions:
- Cardiac iron screening timing in thalassemia major should prioritize age and transfusional burden over general iron overload markers.
- MRI screening can be deferred until age 8 if chelation therapy started at birth and anesthesia is not required.
- Patients with suboptimal chelation, higher transfusion needs, or later transfusion initiation require earlier screening.
Abstract:
We reviewed cardiac T2* assessments from 77 thalassemia major patients between the ages of 2.5 and 18 years to study optimal timing of cardiac iron screening by magnetic resonance imaging. No patient under 9.5 years of age showed detectable cardiac iron in contrast to 36% of patients between the ages of 15-18 years old, corresponding to an odds-ratio of 1.28 (28%) per year. All patients with cardiac iron had received at least 35 grams of transfusional iron. Liver iron and ferritin failed to predict cardiac iron loading. Initiation of cardiac magnetic resonance imaging assessment should be determined according to age and transfusional burden rather than indices of iron overload. When appropriate chelation therapy has been administered since birth, cardiac magnetic resonance imaging can be postponed until 8 years of age when anesthesia is not required. Patients with suboptimal chelation, increased transfusional requirements, or who have initiated transfusions later in life should be tested sooner.
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Dosing: Infants and Children
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Cardiac Performance
